Details of the Drug
General Information of Drug (ID: DM5V3S7)
Drug Name |
Ezetimibe-glucuronide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
ezetimibe-glucuronide; 190448-57-8; Ezetimibe b-D-glucuronide; CHEMBL321017; Ezetimibe beta-D-Glucuronide; Ezetimibe Phenoxy Glucuronide; EZM-G; Sch-58235 Glucuronide; Sch 58235 Glucuronide; A-D-Glucuronide; Ezetimibe Phenexy Glucuronide; Sch 60663; SCHEMBL10027374; CTK8F0579; DTXSID10432454; ZINC3975560; Ezetimibe Phenoxy; BDBM50240720; AKOS030241675; B-D-GLUCOPYRANOSIDURONIC ACID,4-[(2S,3R)-1-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL]-4-OXO-2-AZETIDINYL]PHENYL; RT-012671
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 2 | Molecular Weight (mw) | 585.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 9 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 11 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||